Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
HealthCap
AddedFeb 15, 2024
UpdatedJul 16, 2026
HealthCap

HealthCap

Acquired

Sweden-based HealthCap provides venture capital for innovative life sciences companies, with over 125 investments and 45 IPOs.

Location
Stockholm, Stockholm County, SE
Founded
1996
Firm
Compare
Portfolio
Employees

Investments

Aro Biotherapeutics
Aro Biotherapeutics

Total Raised

$166.5M

Rounds

4

Series B$41.5MNovember 2023
Series A$88MJanuary 2021
Rampart Bioscience
Rampart Bioscience

Total Raised

$85M

Rounds

1

Series A$85MOctober 2023
Spruce Biosciences
Spruce Biosciences
Public

Total Raised

$161.6M

Rounds

4

Post Ipo Equity$53.6MFebruary 2023
Series B$88MFebruary 2020
Carisma Therapeutics
Carisma Therapeutics
Public

Total Raised

$151.9M

Rounds

8

Series C$30MSeptember 2022
Series B$12MMarch 2021
Series B$47MJanuary 2021
Series A$6MAugust 2019
Series A$53MJune 2018
SeedJune 2017
Pretzel Therapeutics
Pretzel Therapeutics

Total Raised

$72.5M

Rounds

2

Series A$72.5MSeptember 2022
InCarda Therapeutics
InCarda Therapeutics
Series A

Total Raised

$86.4M

Rounds

9

Series C$30MOctober 2020
Series B$42MNovember 2018
Rainier Therapeutics
Rainier Therapeutics

Total Raised

$89M

Rounds

5

Series B$20MMay 2018
Series B$30MMarch 2017
Series A$13MJanuary 2016
Series A$6MApril 2014
Tisbury Pharmaceuticals
Tisbury Pharmaceuticals

Total Raised

$32M

Rounds

1

Series A$32MJune 2017
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical
Public

Total Raised

$789.3M

Rounds

6

Series B$75MDecember 2012
Series A$45MJune 2011
Pulmonx
Pulmonx
Public

Total Raised

$276.9M

Rounds

12

Series C$32MMarch 2010
PTC Therapeutics
PTC Therapeutics
Public

Total Raised

$1.6B

Rounds

16

Private Equity$26.6MNovember 2005
Alba Therapeutics
Alba Therapeutics

Total Raised

$30M

Rounds

1

Series A$30MAugust 2005
Sopherion Therapeutics
Sopherion Therapeutics
Acquired

Total Raised

$163M

Rounds

4

Series B$47MSeptember 2004